← Back to Search
Pharmacokinetics And Tissue Distribution Of Idarubicin-loaded Solid Lipid Nanoparticles After Duodenal Administration To Rats.
G. Zara, A. Bargoni, R. Cavalli, A. Fundaró, D. Vighetto, M. Gasco
Published 2002 · Medicine, Chemistry
Download PDFAnalyze on Scholarcy
Idarubicin-loaded solid lipid nanoparticles (IDA-SLN) and idarubicin in solution were prepared and the two formulations were administered to rats, either by the duodenal route or intravenously (iv). The aim of this research was to study whether the bioavailability of idarubicin can be improved by administering IDA-SLN duodenally to rats. Idarubicin and its main metabolite idarubicinol were determined in plasma and tissues by reversed-phase high-performance liquid chromatography. The pharmacokinetic parameters of idarubicin found after duodenal administration of the two formulations were different: area under the curve of concentration versus time (AUC) and elimination half-life were approximately 21 times and 30 times, respectively, higher after IDA-SLN administration than after the solution administration. Tissue distribution also differed: idarubicin and idarubicinol concentrations were lower in heart, lung, spleen, and kidneys after IDA-SLN administration than after solution administration. The drug and its metabolite were detected in the brain only after IDA-SLN administration, indicating that SLN were able to pass the blood-brain barrier. After iv IDA-SLN administration, the AUC of idarubicin was lower than after duodenal administration of the same formulation. Duodenal administration of IDA-SLN modifies the pharmacokinetics and tissue distribution of idarubicin. The IDA-SLN act as a prolonged release system for the drug.
This paper references
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
A. Ward (1987)
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel.
A. Miglietta (2000)
Evaluation of nano- and microparticle uptake by the gastrointestinal tract.
Synthesis of daunorubicin analogues with novel 9-acyl substituents.
T. H. Smith (1979)
NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium(III) complexes.
S. Morel (1998)
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats.
A. Fundaró (2000)
F. Ganzina (2004)
P. Singal (1998)
Thymopentin in solid lipid nanoparticles
S. Morel (1996)
Biodistribution of Stealth and Non‐stealth Solid Lipid Nanospheres after Intravenous Administration to Rats
Valerio Podio (2000)
Idarubicin: a brief overview on pharmacology and clinical use.
P. Borchmann (1997)
P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier.
A. Tsuji (1998)
Clinical Pharmacokinetics of Idarubicin
J. Robert (1993)
Solid Lipid Nanoparticles in Lymph and Plasma After Duodenal Administration to Rats
A. Bargoni (2004)
Antitumor activity of 4-demethoxydaunorubicin administered orally.
A. di Marco (1977)
Induction of apoptosis by idarubicin: how important is the plasma peak?
F. Gieseler (2000)
Nanoparticle technology for delivery of drugs across the blood-brain barrier.
U. Schroeder (1998)
The Transfer of Polystyrene Microspheres from the Gastrointestinal Tract to the Circulation after Oral Administration in the Rat
J. Eyles (1995)
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Shicheng Yang (2004)
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
D. J. Roovers (1999)
Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I--a pharmacokinetic study.
R. Cavalli (2000)
Solid lipospheres of doxorubicin and idarubicin
R. Cavalli (1993)
Aspects of cytotoxic drug penetration, with particular reference to anthracyclines
D. Kerr (2004)
Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence.
A. Florence (1995)
Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
J. Reid (1990)
Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)
K. Lu (2004)
Analysis of Macromolecular Polydispersity in Intensity Correlation Spectroscopy: The Method of Cumulants
D. Koppel (1972)
Nanoparticulate systems for brain delivery of drugs.
J. Kreuter (2001)
Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses
S. Kaplan (2004)
High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue.
L. Rose (1988)
New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier
C. Damgé (1988)
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
M. Buckley (1997)
Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles
P. Beck (1994)
Analysis of 4-demethoxydaunorubicin and metabolites in plasma and urine.
J. Beijnen (1988)
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
J. Kreuter (1995)
Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4‐demethoxydaunomycin
Paul A J Speth (1986)
This paper is referenced by
Brain Delivery by Nanoparticles
S. Gelperina (2006)
Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.
Rishi Paliwal (2009)
Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
M. K. Rawat (2010)
Diagnosing Biopharmaceutical Limitations
S. Jenkins (2015)
Development, characterization and evaluation of solid lipid nanoparticles as a potential anticancer drug delivery system
M. Patel (2012)
Optimising nanomedicine pharmacokinetics using PBPK modelling
D. Moss (2017)
Pharmaceutical Applications of Nanoparticulate Drug-Delivery Systems
Y. Pathak (2007)
Cholesterylbutyrate Solid Lipid Nanoparticles as a Butyric Acid Prodrug
A. Brioschi (2008)
Delivery Systems for Lymphatic Targeting
I. Singh (2013)
Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion.
Srinivas Ganta (2008)
Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art.
L. Gastaldi (2014)
Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles.
V. Venkateswarlu (2004)
Delivery of peptide and protein drugs over the blood–brain barrier
I. Brasnjevic (2009)
Multifunctional Polymeric Nanosystems for Tumor-Targeted Delivery
P. Magadala (2008)
Nanostructured Lipid Carriers (NLC) in dermal and personal care formulations
A. Hommoss (2009)
Engineering lipid nanocapsule systems for intracellular delivery of anticancer drugs
P. Moreno (2014)
DRUG DELIVERY SYSTEMS PROVIDE BETTER OPTION FOR MANAGEMENT OF TUBERCLULOSIS
M. Raja (2002)
Solid lipid nanoparticles for brain tumors therapy
A. Brioschi (2009)
ApoE‐modified solid lipid nanoparticles: A feasible strategy to cross the blood‐brain barrier
R. Dal Magro (2017)
Solid lipid nanoparticles :A promising tool for drug delivery system
B. Basu (2010)
Nanostructured Lipid Carriers (NLC): The Second Generation of Solid Lipid Nanoparticles
R. Mueller (2016)
Chapter 11 - Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges.
A. Brioschi (2009)
NANOSTRUCTURE LIPID CARRIERS (NLC) FOR TOPICAL APPLICATION: A REVIEW
Gajanan Y. Shinde (2013)
Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.
P. Ma (2009)
New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin.
M. Garcia-Fuentes (2005)
Mikrosfery lipidowe jako nowa postać leku pozajelitowego : opracowanie metody sporządzania i próba inkorporacji substancji leczniczych
J. Pietkiewicz (2005)
Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
Derajram M Benival (2012)
Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.
K. Manjunath (2005)
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
M. K. Rawat (2011)
Polypeptide conjugates of D-penicillamine and idarubicin for anticancer therapy.
S. Wadhwa (2012)
Solid Lipid Nanoparticles: Tuneable Anti-Cancer Gene/Drug Delivery Systems
Tranum Kaur (2013)
Nanoparticles fabricated from bulk solid lipids: Preparation, properties, and potential food applications.
Q. Zhong (2019)See more